Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial
DOIAbstract
none10noThe aim of this prospective clinical trial was to evaluate the efficacy and safety of a combination of Gemtuzumab-Ozogamicin (GO) and FLAI scheme (fludarabine, cytarabine, idarubicin) as a first-line therapy in CD33 positive acute myeloid leukemia (AML). We treated 130 consecutive patients, aged <65, with a median age of 52 years (range, 18-65). FLAI-GO induction regimen included fludarabine (30 mg/sqm) and cytarabine (2 g/sqm) on days 1-5; idarubicin (10 mg/sqm) on days 1, 3, and 5; and GO (3 mg/sqm) on day 6. Hematopoietic stem cell transplant (SCT) was planned for all high-risk AML patients, after consolidation with intermediate doses of cytarabine and idarubicin (AC-IDA) and a high dose of cytarabine. CD33 expression exceeded 20...
Add to ORKG